Summary
Lymphocytosis is a marker of subcutaneous interleukin (IL)-2 therapy efficacy, whereas baseline elevated inflammatory indices were noticed in IL-2-resistant disease. The aim of this study was to analyse the relationship between pretreatment circulating values of IL-6, neopterin, sIL-2R, ESR and the changes in lymphocyte number in response to IL-2 administration. Twenty metastatic renal cell cancer patients were treated with subcutaneous IL-2 immunotherapy (6 000 000 IU day–1 for 6 days per week for 4 weeks); tumour response consisted of partial response (PR) in four patients, stable disease (SD) in eight patients and progressive disease (PD) in eight patients. Abnormally high pretreatment values of each marker were found as follows: IL-6 in seven patients, neopterin in nine patients, sIL-2R in 13 patients. In response to IL-2 immunotherapy, a significantly higher mean increase in lymphocyte number and a higher percentage of patients with tumour response or stable disease were observed when pretreatment values of IL-6, neopterin and sIL-2R were within the normal range, in comparison to patients with high values for these markers. The pretreatment excess of these serum inflammatory markers seems to negatively influence both the host and tumour response to IL-2 administration, by preventing the IL-2-induced lymphocytosis and resulting in tumour progression. Further studies are requested to verify if overall survival and quality of life may depend on pretreatment host immune status and/or lymphocyte response after IL-2 administration.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
American Society of Clinical Oncology (1996). Outcomes of cancer treatment for technology assessment and cancer treatment guidelines (Special Article). J Clin Oncol 14: 671–679.
Blay, J. Y., Negrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., Moskovtchenko, J. F., Philip, T. & Favrot, M. (1992). Serum levels of IL-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 52: 3317–3322.
Buzio, G., De Palma, G., Passalacqua, R., Potenzoni, D., Ferrozzi, F., Cattabiani, M. A., Manenti, L. & Borghetti, A. (1997). Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 76: 541–544.
Chouaib, S. & Fradelizi, D. (1982). The mechanism of inhibiton of human IL-2 production. J Immunol 129: 2463–2468.
Diamondstone, L. S., Tollerud, D. J., Fuchs, D., Wachter, H., Brown, L. M., Maloney, E., Kurman, C., Nelson, D. L. & Blattner, W. A. (1994). Factors influencing serum neopterin and beta-2 microglobulin levels in a healthy diverse population. J Clin Immunol 14: 368–373.
Figlin, R., Gitlitz, B., Franklin, J., Dorey, F., Moldawer, N., Rausch, J., deKernion, J. & Belldegrun, A. (1997). Interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 3: S92–97.
Fischer, J. R., Schindel, M., Stein, N., Lahm, H., Gallati, H., Krammer, P. H. & Drings, P. (1995). Selective suppression of cytokine secretion in patients with SCLC. Ann Oncol 6: 921–926.
Gastl, G., Abrams, J. S., Nanus, D. M., Oosterkamp, R., Silver, J., Liu, F., Chen, M., Albino, A. P. & Bander, N. H. (1993). IL-10 production by human carcinoma cell lines and its relationship to IL-6 expression. Int J Cancer 55: 96–101.
Gohring, B., Riemann, D., Rebmann, U., Heynemann, H., Schabel, J. & Langner, J. (1996). Prognostic value of immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-α in combination with 5-FU. Urol Res 24: 297–303.
Gooding, R., Riches, P., Dadian, G., Moore, J. & Gore, M. (1995). Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 72: 452–455.
Grimm, E. A., Mazumder, A., Zhang, H. Z. & Rosenberg, S. A. (1982). Lymphokine-activated killer cell phenomenon. J Exp Med 155: 1823–1841.
Jeal, W. & Goa, K. L. (1997). Aldesleukin (recombinant Interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. Bio Drugs 7: 285–317.
Katsumata, N., Eguchi, K., Fukuda, M., Yamamoto, N., Ohe, Y., Oshita, F., Tamura, T., Shinkai, T. & Saijo, N. (1996). Serum levels of cytokines in patients with untreated lung cancer. Clin Cancer Res 2: 553–559.
Kim, U. S., Papatestas, A. E. & Aufses, A. H. (1976). Prognostic significance of peripheral lymphocyte counts and carcinoembryonic antigens in colorectal carcinoma. J Surg Oncol 8(3): 257–62.
Kishimoto, T. (1989). The biology of interleukin-6. Blood 74: 1–10.
Koo, A. C., Armstrong, C., Bochner, B., Shimabukuro, T., Tso, C. L., deKernion, J. B. & Belldegrun, A. (1992). IL-6 and renal cell cancer: production, regulation and growth effects. Cancer Immunol Immunother 35: 97–105.
Lissoni, P., Viviani, S., Santoro, A., Barni, S. & Tancini, G. (1989). Serum levels of Interleukin-2 in cancer patients: preliminary considerations. Int J Biol Marker 4: 203–206.
Lissoni, P., Brivio, F., Fumagalli, L., Galimberti, C., Cataldo, M., Marsili, M. T., Brivio, O., Barni, S., Tancini, G. & Angelini, A. (1994). A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis-alpha and of soluble interleukin-2 receptors. J Biol Regul Homeost Agents 8: 32–35.
Lissoni, P., Fumagalli, L., Rovelli, F., Brivio, F., Di Felice, G. & Maiorca, F. (1998). In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. Br J Cancer (in press)
Lopez Hanninen, E., Kirchner, H. & Atzpodien, J. (1996). IL-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urology 155: 19–25.
Maltoni, M., Pirovano, M., Nanni, O., Marinari, M., Indelli, M., Gramazio, A., Terzoli, E., Luzzani, M., De Marinis, F., Caraceni, A. & Labianca, R. (1997). Biological indices predictive of survival in 519 italian terminally ill cancer patients. J Pain Symptom Manage 13: 1–9.
Monson, J. R. T., Ramsden, C. & Guillou, P. J. (1986). Decreased IL-2 production in patients with gastrointestinal cancer. Br J Surg 73: 483–486.
Palmer, P. A., Vinke, J., Philip, T., Negrier, S., Atzpodien, J., Kirchner, H., Oskam, R. & Franks, C. R. (1992). Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant IL-2. Ann Oncology 3: 475–480.
Palmer, P. A., Atzpodien, J., Philip, T., Negrier, S., Kirchner, H., Von der Maase, H., Geertsen, P., Evers, P., Loriaux, E., Oskam, R., Roest, G., Vinke, J. & Franks, C. R. (1993). A comparison of 2 modes of administration of rIL-2: continuous intravenous infusion alone versus subcutaneous administration plus IFN-a in patients with advanced renal cell carcinoma. Cancer Bioth 8: 123–135.
Riesco, A. (1970). Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25: 135–140.
Rubin, L. A., Kurman, C. C. & Fritz, M. E. (1985). Soluble IL-2 receptors are released by activated lymphocytes in vitro. J Immunol 135: 3172–3177.
Rubin, L. A., Jay, G. & Nelson, D. L. (1986). The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 137: 3841–3384.
Scheid, C., Young, R. & McDermott, R. (1994). Immune function of patients receiving recombinant human IL-6 in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 38: 119–126.
Schoof, D. D., Douville, L., Terashima, Y., Richie, J. P., Batter, S. & Eberlein, T. J. (1993). Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2. Urology 41: 534–539.
Scott, H. R., McMillan, D. C., Crilly, A., McArdle, C. S. & Milroy, R. (1996). The relationship between weight loss and interleukin-6 in non-small cell lung cancer. Br J Cancer 73: 1560–1562.
Sedlmayr, P., Rabinowich, H., Elder, E., Ernstoff, M. S., Kirkwood, J. M., Herberman, R. B. & Whiteside, T. (1991). Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine activate killer cells. J Immunother 10: 336–346.
Stanley, K. E. (1980). Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65: 25–32.
Tanner, J. & Tosato, G. (1991). Impairment of natural killer functions by interleukin-6 increases lymphoblistoid cell tumorigenicity in athymic mice. J Clin Invest 88: 239–247.
Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., Montero, F., Joueux, I., Pouillart, P. & Fridman, W. H. (1994). Serum Interleukin-6 levels and CRP correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69: 911–913.
Walther, M. M., Johnson, B., Culley, D., Shah, R., Weber, J., Venzon, D., Yang, J. C., Linehan, W. M. & Rosenberg, S. A. (1998). Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 159: 718–722.
Wojtowicz-Praga, S. (1997). Reversal of tumor indiced immunosuppression: a new approach to cancer therapy. J Immunother 20: 165–177.
Yoshino, I., Yano, T., Murata, M., Ishida, T., Sugimachi, K., Kimura, G. & Nomoto, K. (1992). Tumor-reactive T cells accumulate in lung cancer tissues but fail to respond due to tumor cell derived factors. Cancer Res 52: 775–781.
Zorn, U., Dallmann, I., Grosse, J., Kirchner, H., Poliwoda, H. & Atzpodien, J. (1994). Soluble interleukin-2 receptors abrogate IL-2-induced activation of peripheral mononuclear cells. Cytokine 6: 358–364.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Fumagalli, L., Lissoni, P., Felice, G. et al. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 80, 407–411 (1999). https://doi.org/10.1038/sj.bjc.6690371
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690371
Keywords
This article is cited by
-
Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis
Clinical and Translational Oncology (2020)
-
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
British Journal of Cancer (2010)
-
A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer
Cancer Immunology, Immunotherapy (2010)
-
Serum neopterin levels in patients with breast cancer
Medical Oncology (2008)
